Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SOHO 2023 | The current state-of-the-art in PV and future outlooks

Francesco Passamonti • 7 Sep 2023
SOHO 2023
Myeloproliferative Neoplasms Polycythemia Vera Rare Diseases Hydroxyurea Ropeginterferon alfa-2b Ruxolitinib
MAJIC-PV

Francesco Passamonti, MD, University of Insubria, Varese, Italy, briefly discusses the current state-of-the-art in polycythemia vera (PV), highlighting the value of agents including ropeginterferon alfa-2b and ruxolitinib. This interview took place at the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023) held in Houston, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Francesco Passamonti

1:00
Current and emerging treatment options for anemia in MF
Francesco Passamonti • 7 Sep 2023
1:13
Results from the ACE‐536‐MF‐001 study
Francesco Passamonti • 7 Sep 2023
1:14
Modern prognostication in MPNs: improving risk stratification & treatment approaches
Francesco Passamonti • 7 Sep 2023
1:30
Optimal approach to first-line therapy in myelofibrosis
Francesco Passamonti • 11 Jun 2022

Related Videos

3:18
Immune-mediated bone marrow failure diseases & their pathophysiology: aplastic anemia, LR-MDS & PNH
Carlo Dufour • 15 Apr 2024
2:05
Donor lymphocyte infusion for relapsed myelofibrosis in the post-alloSCT setting
Alex Rampotas • 16 Apr 2024
1:11
Personalized risk assessment for transplantation in primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
1:18
Autologous gene editing using the CRISPR system to treat primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals